November 12, 2020 -- Moderna has completed case accrual for its first interim analysis of a phase III study of its COVID-19 vaccine candidate.
The trial includes 30,000 U.S. participants, and is investigating the use of the COVID-19 vaccine candidate messenger RNA (mRNA)-1273 at a dose of 100 µg. It was designed to evaluate individuals at higher risk of severe COVID-19 disease and included more than 7,000 U.S. adults over the age of 65. Interim data will be submitted to the Data Safety Monitoring Board (DSMB).
Moderna developed the vaccine candidate in collaboration with the U.S. National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center, it said. The research and development of mRNA-1273 is supported by $955 million in federal funding from the Biomedical Advanced Research and Development Authority (BARDA). The U.S. government has committed up to $1.5 billion to purchase supply of the vaccine once it has been validated, according to Moderna.